Hepatology

Papers
(The TQCC of Hepatology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies1599
Plasma proteomic signature of fatty liver disease: The Rotterdam Study1394
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study1273
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis789
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals512
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice437
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma358
Efficacy and safety of infliximab in patients with autoimmune hepatitis286
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma263
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death224
Retracted207
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease203
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1198
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model190
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution178
Cover Image171
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency166
Late-Breaking Abstracts161
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol160
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients156
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks156
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive155
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s151
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury151
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet146
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!136
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention130
REPLY:125
Reply124
Alan Hofmann (1931‐2021): A career well spent understanding bile acids124
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?123
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC122
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis119
Reply: Medications promoting abstinence in alcohol-associated cirrhosis118
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis118
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy117
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension117
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor116
Access to technology to support telehealth in areas without specialty care for liver disease113
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction-associated steatosis111
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates110
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH106
Letter to the editor: The precise relationship between MELD and survival without a liver transplant105
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis105
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST105
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway104
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8102
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction101
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice100
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression99
Regulatory role and translational potential of CCL11 in liver fibrosis98
97
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease97
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma94
93
Instructions to Authors91
Letter to the editor89
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?88
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study87
Erratum87
Healthy peribiliary glands are necessary for successful liver transplantation87
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma86
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis83
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis82
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?82
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty80
Letter to the Editor: Overlooking the important factor: Hypoxia80
Reply80
Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells79
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes79
REPLY:78
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms77
In vivo imaging of calcium dynamics in zebrafish hepatocytes77
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation76
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination76
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis76
Letter to the Editor76
Much more needed in natural history of Alagille syndrome75
Hepatology Highlights75
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer73
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism72
To Be or Not to Be72
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease72
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers71
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study71
With Alcohol as the Fuel, COVID Is the Match71
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement71
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment70
Endpoints and New Options for Treatment of Chronic Hepatitis D69
Fontan‐associated liver disease68
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma68
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats67
The international quest for the imaging diagnosis of liver cancer67
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known67
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia67
Therapeutic manipulation of the microbiome in liver disease66
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation66
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?65
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis64
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis64
The digital determinants of liver disease64
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH63
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans63
Genes that fit just right: Unzipping the genome of fatty liver disease63
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study62
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?62
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm62
NAFLD‐related hepatocellular carcinoma: The growing challenge61
Metabolic dysfunction-associated steatotic liver disease and the heart61
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men61
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome60
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis60
Immunobiology of primary sclerosing cholangitis60
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response59
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature59
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity59
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study58
A strategy of vascular‐targeted therapy for liver fibrosis58
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality58
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness58
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via non-canonical phosphorylation58
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease57
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh57
Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression57
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent57
Enoxacin Up‐Regulates MicroRNA Biogenesis and Down‐Regulates Cytotoxic CD8 T‐Cell Function in Autoimmune Cholangitis56
The clot and the complicated consult56
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis56
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?55
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block55
Reply55
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles55
Reply54
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?54
REPLY:54
Hepatology Highlights54
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study53
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia53
Manuscript best practices: Takeaways from a community conversation53
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease53
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy52
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease52
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis51
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling51
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC51
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”51
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood51
Reply51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis51
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study51
Reply50
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?50
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis50
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States49
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)49
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort49
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy49
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion49
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases49
Reply49
Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function48
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution48
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants48
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase48
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol48
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease47
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study47
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation47
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma47
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS47
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies47
Future directions in acute liver failure46
Pathway to global elimination of hepatitis B: HBV cure is just the first step46
Oral Abstracts46
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features46
Table of contents45
Cover Image45
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices45
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia45
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!45
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?45
Table of contents45
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies44
Reply44
Masthead44
Masthead43
Cover Image43
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α43
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?43
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial42
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease42
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis42
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma42
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study42
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon42
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?42
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease42
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation42
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations41
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency41
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs41
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions40
Letter to the editor: HuR in liver homeostasis40
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease40
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC40
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study40
Imaging for better responses to immunotherapy in hepatocellular carcinoma40
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis40
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors40
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 740
Reply40
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?39
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease39
Presenting the new incoming editorial team for hepatology: Team members and perspectives39
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations39
Letter to the Editor: More questions than answers—Response to the POP-NEXT project39
Predicting liver outcomes with biomarker monitoring in MASLD38
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west38
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys38
Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model38
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality38
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury38
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis38
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD38
Telehealth interventions in patients with chronic liver diseases: A systematic review38
Intrahepatic cholangiocarcinoma PANoptosidy37
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study37
Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis37
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis37
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges37
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets37
Dissecting liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure37
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma37
Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy37
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway37
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI36
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis36
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma36
A global action agenda for turning the tide on fatty liver disease36
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC36
Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes36
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis36
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population36
Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells36
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing36
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab36
Category Index35
Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding35
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB35
0.04440712928772